SG10202007364RA - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
SG10202007364RA
SG10202007364RA SG10202007364RA SG10202007364RA SG10202007364RA SG 10202007364R A SG10202007364R A SG 10202007364RA SG 10202007364R A SG10202007364R A SG 10202007364RA SG 10202007364R A SG10202007364R A SG 10202007364RA SG 10202007364R A SG10202007364R A SG 10202007364RA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
SG10202007364RA
Inventor
Nicholas Mcgranahan
Rachel Rosenthal
Charles Swanton
Karl Peggs
Sergio Quezada
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507100.4A external-priority patent/GB201507100D0/en
Priority claimed from GBGB1603663.4A external-priority patent/GB201603663D0/en
Priority claimed from GBGB1603731.9A external-priority patent/GB201603731D0/en
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of SG10202007364RA publication Critical patent/SG10202007364RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464401Neoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57Skin; melanoma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/505CD4; CD8
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121Dendritic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/99Coculture with; Conditioned medium produced by genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG10202007364RA 2015-04-27 2016-04-27 Method for treating cancer SG10202007364RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507100.4A GB201507100D0 (en) 2015-04-27 2015-04-27 Method
GBGB1603663.4A GB201603663D0 (en) 2016-03-02 2016-03-02 Method
GBGB1603731.9A GB201603731D0 (en) 2016-03-03 2016-03-03 Method

Publications (1)

Publication Number Publication Date
SG10202007364RA true SG10202007364RA (en) 2020-09-29

Family

ID=55809140

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007364RA SG10202007364RA (en) 2015-04-27 2016-04-27 Method for treating cancer
SG11201707920YA SG11201707920YA (en) 2015-04-27 2016-04-27 Method for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707920YA SG11201707920YA (en) 2015-04-27 2016-04-27 Method for treating cancer

Country Status (22)

Country Link
US (3) US20180064793A1 (en)
EP (4) EP4137151A1 (en)
JP (4) JP6918703B2 (en)
KR (2) KR102629590B1 (en)
CN (2) CN107750278B (en)
AU (2) AU2016256220B2 (en)
BR (1) BR112017020893A2 (en)
CA (1) CA2982266A1 (en)
CL (2) CL2017002728A1 (en)
DK (1) DK3288581T3 (en)
ES (1) ES2836273T3 (en)
HU (1) HUE052106T2 (en)
IL (2) IL298497A (en)
MX (1) MX2017013777A (en)
MY (1) MY189338A (en)
NZ (1) NZ735882A (en)
PL (1) PL3288581T3 (en)
PT (1) PT3288581T (en)
RU (2) RU2020123735A (en)
SG (2) SG10202007364RA (en)
WO (1) WO2016174085A1 (en)
ZA (1) ZA201706616B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3389630B1 (en) 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP2020507557A (en) * 2016-12-01 2020-03-12 ナントミクス,エルエルシー Processing and presentation of tumor antigenicity
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3051869A1 (en) * 2017-02-07 2018-08-16 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy
TWI672503B (en) * 2017-03-31 2019-09-21 行動基因生技股份有限公司 Ranking system for immunogenic cancer-specific epitopes
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
KR20200090855A (en) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 Reduced presentation of conjugated epitopes for new antigens
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
EP3844776A1 (en) * 2018-08-28 2021-07-07 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
CN109295097B (en) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 MRFFT2 cell
CN109294997B (en) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 LRFFT1 cell
CN109337873A (en) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 A kind of LRFF cell
CN109485721A (en) * 2018-11-23 2019-03-19 杜学明 A method of obtaining tumor specific T cells receptor
CA3124905A1 (en) * 2019-01-03 2020-07-09 Jens KRINGELUM Vaccines targeting neoepitopes
CN110534156B (en) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 Method and system for extracting immunotherapy new antigen
CN110689930B (en) * 2019-10-18 2021-07-30 北京橡鑫生物科技有限公司 Method and device for detecting TMB
WO2021087839A1 (en) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 Tumor-specific polypeptide sequence and application thereof
JP2023505726A (en) * 2019-12-12 2023-02-10 アキレス セラピューティクス ユーケー リミテッド Methods of obtaining nucleic acids for sequencing
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021163695A2 (en) * 2020-02-14 2021-08-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel t cell receptors (tcrs) that react to neoantigens
CN111303268B (en) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 Hysteromyoma neoantigen, application thereof and hysteromyoma vaccine
JP2022024683A (en) 2020-07-28 2022-02-09 株式会社ミツトヨ Method for measuring shape
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205135D0 (en) 2022-04-07 2022-05-25 Francis Crick Institute Ltd Analysis of HLA alleles transcriptional deregulation
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
WO2023194491A1 (en) 2022-04-07 2023-10-12 The Francis Crick Institute Limited Analysis of hla alleles transcriptional deregulation
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024034622A1 (en) * 2022-08-08 2024-02-15 北海道公立大学法人 札幌医科大学 Method for selecting subject-derived neoantigen
GB202213928D0 (en) 2022-09-23 2022-11-09 Achilles Therapeutics Uk Ltd Allele specific expression
CN117535352A (en) * 2023-10-16 2024-02-09 同济大学 Method for screening T cells with POLE antigen specificity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2209633C2 (en) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа T-cellular vaccine for cerebrospinal sclerosis treatment
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
EP3699266A1 (en) * 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
WO2012159754A2 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
ES2729759T3 (en) * 2012-07-12 2019-11-06 Persimmune Inc Customized cancer vaccines and adoptive immune cell therapies
WO2014026096A1 (en) * 2012-08-10 2014-02-13 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
KR102341899B1 (en) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN106456724A (en) * 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
TWI755158B (en) * 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method

Also Published As

Publication number Publication date
NZ735882A (en) 2022-07-29
CA2982266A1 (en) 2016-11-03
JP6918703B2 (en) 2021-08-11
CL2020001730A1 (en) 2020-11-06
DK3288581T3 (en) 2021-01-11
IL254760A (en) 2017-12-31
IL254760B2 (en) 2023-05-01
JP2024001069A (en) 2024-01-09
EP3603665A1 (en) 2020-02-05
CN107750278A (en) 2018-03-02
AU2016256220B2 (en) 2021-10-21
JP2020127404A (en) 2020-08-27
KR20170138560A (en) 2017-12-15
PL3288581T3 (en) 2021-05-31
RU2017134504A3 (en) 2020-08-12
MX2017013777A (en) 2018-03-27
SG11201707920YA (en) 2017-11-29
CL2017002728A1 (en) 2018-06-22
KR20230125090A (en) 2023-08-28
RU2020123735A (en) 2020-07-30
ZA201706616B (en) 2021-03-31
RU2770447C2 (en) 2022-04-18
AU2016256220A1 (en) 2017-10-19
AU2021286241A1 (en) 2022-01-06
KR102629590B1 (en) 2024-01-24
RU2017134504A (en) 2019-04-04
PT3288581T (en) 2020-12-04
US20200000903A1 (en) 2020-01-02
US20180064793A1 (en) 2018-03-08
HUE052106T2 (en) 2021-04-28
CN107750278B (en) 2023-10-03
CN117467603A (en) 2024-01-30
WO2016174085A1 (en) 2016-11-03
IL298497A (en) 2023-01-01
EP3603666A1 (en) 2020-02-05
EP3288581A1 (en) 2018-03-07
US20200000904A1 (en) 2020-01-02
MY189338A (en) 2022-02-04
EP4137151A1 (en) 2023-02-22
ES2836273T3 (en) 2021-06-24
IL254760B1 (en) 2023-01-01
JP2022008381A (en) 2022-01-13
JP2018520637A (en) 2018-08-02
BR112017020893A2 (en) 2018-07-10
EP3288581B1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
ZA201706616B (en) Method for treating cancer
HK1251407A1 (en) Methods for treating cancer
IL304252A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
IL257691A (en) Method for treating cancer
EP3110509A4 (en) Method for treating cancer
HK1254258A1 (en) Methods for treating cancer using apilimod
HK1244217A1 (en) Methods for treating proteinopathies
EP3389634A4 (en) Methods for treating cancer
HK1250944A1 (en) Methods for treating cancer
HK1248135A1 (en) Combination method for treating cancer
EP3389652A4 (en) Methods for treating cancer
HK1250942A1 (en) Methods for treating cancer
IL246558A0 (en) Novel methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
EP3247376A4 (en) Method for treating cancer
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (en) Methods for treating tumours